SOURCE: Equity News Circuit

Equity News Circuit

April 03, 2013 08:45 ET

Free Research Reports on ASTX, EHTH, EZPW and OPTR Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - Apr 3, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) shares spiked 10.50 percent on volume of over 4.0 million shares traded Tuesday to close at $5.05 a share. The company reported a net income of $4.5 million for the fourth quarter of 2012. Astex Pharmaceuticals is expected to release results for the first quarter of 2013 on Monday, April 29th.

Find out more about Astex Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/ASTX

eHealth, Inc. (NASDAQ: EHTH) shares surged 15.72 percent on volume of over 1.0 million shares traded Tuesday to close at $20.46 a share. Nat Schindler for Bank of America Merrill Lynch and Richard Fetyko of Janney Capital Markets have both recently upgraded the company to a "buy" rating.

Find out more about eHealth including full access to the free equity report at: www.BedfordReport.com/EHTH

EZCORP Inc. (NASDAQ: EZPW) shares declined 6.09 percent on more than four times the average daily volume Tuesday to close at $19.58 a share. FBR has recently downgraded the company's rating to "underperform" and have lowered its price target from $22 to $17.50.

Find out more about EZCORP including full access to the free equity report at: www.BedfordReport.com/EZPW

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) shares soared 19.19 percent on more than four times the average daily volume Tuesday to close at $13.91 a share. Bloomberg has recently reported that the biotech company is drawing takeover interest from GlaxoSmithKline Plc and Astellas Pharma Inc.

Find out more about Optimer Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/OPTR

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information